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Murine Transporter Associated with Antigen Presentation
(TAP) Preferences Influence Class I–restricted
T Cell Responses
By Amy J.Yellen-Shaw,* Carol E. Laughlin,* Robert M. Metrione,‡
and Laurence C. Eisenlohr*
From the *Kimmel Cancer Institute and ‡Department of Biochemistry and Molecular Pharmacology,
Jefferson Medical College,Thomas Jefferson University, Philadelphia, Pennsylvania 19107

Summary
The transporter associated with antigen presentation (TAP) complex shuttles cytosolic peptides
into the exocytic compartment for association with nascent major histocompatibility complex
class I molecules. Biochemical studies of murine and human TAP have established that substrate length and COOH-terminal residue identity are strong determinants of transport efficiency. However, the existence of these specificities in the intact cell and their influences on T
cell responses have not been demonstrated. We have devised a method for studying TAPmediated transport in intact cells, using T cell activation as a readout. The approach makes use
of a panel of recombinant vaccinia viruses expressing peptides containing the Kd-restricted
nonamer influenza nucleoprotein residues 147–155. The COOH terminus of each construct
was appended with a dipeptide composed of an internal threonine residue followed by a varying amino acid. Synthetic peptide versions of these 11-mers exhibit vastly different transport
capabilities in streptolysin O–permeabilized cells, in accordance with the predicted influence of
the COOH-terminal residues. Presentation of the endogenously expressed version of each
construct requires TAP-mediated transport and cooexpression with a vac-encoded exocytic
COOH-terminal dipeptidase, angiotensin converting enzyme, to allow liberation of the minimal epitope. Recognition by epitope-specific CTLs therefore signifies TAP-mediated transport
of a complete 11-mer within the target cell. Under normal assay conditions no influences of
the COOH-terminal residue were revealed. However, when T cell recognition was limited,
either by blocking CD8 coreceptor interactions or by decreasing the amount of transport substrate synthesized, significant COOH-terminal effects were revealed. Under such conditions,
those peptides that transported poorly in biochemical assays were less efficiently presented.
Therefore, TAP specificity operates in the intact cell, appears to reflect previously defined rules
with regard to the influence of the COOH-terminal residue, and can strongly influence T cell
responses.
D81 CTLs recognize short (8–10-amino acid) peptide
portions of antigen (epitopes) complexed with major
histocompatibility class I molecules (1–3). The initial processing of most antigens destined for recognition by class
I–restricted CTLs occurs in the cytosol. The resultant fragments are then conveyed to the exocytic compartment by
the transporter associated with antigen presentation (TAP)1
heterodimer where, perhaps after further processing, they
become available for binding to nascent class I. Because of
this function, the TAP complex, a member of the ABC
family of transporters (4, 5), is critical for presentation of

C

1 Abbreviations used in this paper: ACE, angiotensin converting enzyme;
IC50, 50% inhibitory concentration; NP, influenza nucleoprotein; TAP,
transporter associated with antigen presentation; TE, 147–155TE; TG,
147–155TG; TL, 147–155TL; TM, 147–155TM; TP, 147–155TP; TX,
147–155TX; vac, vaccinia.
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the vast majority of class I–restricted epitopes, as well as for
the surface expression of class I molecules themselves (6).
Numerous potential epitopes are contained within an
antigenic protein, but very few trigger CTL responses. Although much of this selectivity can be attributed to stringent haplotype-specific class I binding requirements (7),
other factors determining epitope immunogenicity include
the availability of appropriate T cell specificities and the
ability of the proteolytic machinery to excise the epitope
without destroying it too rapidly (8, 9). As understanding
of the critical role of TAP in class I–restricted antigen presentation has grown, it has been intriguing to speculate that
TAP substrate specificity may also have a significant hand
in determining which epitopes are available for T cell recognition.
It was initially observed that polymorphism at the rat cim
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locus, the TAP homologue in that species, could be correlated with variability in the array of class I–associated peptides (10). This finding was of particular significance because it implied an influence of transport specificity in a
relatively unmanipulated system. Although the cim effect
could be shown to influence T cell responses in the rat, it is
important to note that the cim locus exhibits far greater
variability than does the TAP locus in either mice or humans (3). This approach, applied to a study of class I–associated peptides in mice and humans, has failed to identify a
similar influence of allelic variation on TAP specificity (11,
12). However, in vitro biochemical assays, using either
streptolysin O–permeabilized cells or isolated microsomes,
have provided evidence for substrate preferences by all
TAP alleles in both species (13–18). By these means, a size
optimum of 8–12 residues has been established, and it has
been found that mouse TAPs prefer peptides with hydrophobic COOH-terminal residues; human TAPs transport
peptides with both hydrophobic and acidic COOH termini
(19, 20). These preferences are consistent with MHC binding capabilities and this, along with the genetic linkage between TAP and MHC (3), has given rise to the speculation
that the two have coevolved to enhance the efficiency of
the class I–restricted response. To date, these biochemical
assays provide the only evidence for murine or human
TAP selectivity; as yet it is undemonstrated whether the
measured preferences have significance for T cell recognition.
Some evidence suggests that murine TAP specificity may
not play a large role in shaping T cell responses. It is clear
that substrates showing little or no transport capability in in
vitro transport assays can be presented to T cells and serve
as potent immunogens in vivo. Shepherd et al. previously
reported that the minimal epitope influenza nucleoprotein
residues 147–155 (NP147–155) is not detectably transported
into isolated microsomes, with a 50% inhibitory concentration (IC50) value of .50 mM (14). Although these authors
suggested that a longer fragment containing the epitope
may be transported and further processed in the exocytic
compartment, a minigene expressing only the minimal
epitope is a more efficient immunogen than full-length NP
(21, 22). Furthermore, it has been reported that cells expressing murine TAP and the human HLA-A3 gene product can efficiently produce ligands for this class I molecule
despite its preference for positively charged COOH termini (23), which are likely to be generated before transport
(24). Given the high sensitivity of T cells, it is possible that
TAP selectivity may not significantly impact their responses
under physiological conditions. Additionally, as with in vitro
nuclear transport assays (25), streptolysin O and microsome
isolation may lead to a loss of molecules that influence
transport in vivo. It is possible that such molecules physically interact with the TAP complex, processed fragments,
or both, to influence transport specificity and/or rates.
Therefore, we wished to test whether biochemically established transport capability was in fact correlated with TAP
selectivity within intact cells and, if so, begin to elucidate
conditions of antigen expression and CTL sensitivity under
which selectivity might influence an immune response.
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Figure 1. Schematic diagram
of transport-dependent ACEmediated processing in the exocytic compartment.

In this study, we describe a unique approach to measuring the influence of TAP specificity within live, intact cells,
using the physiologically significant readout of CTL recognition. A previous study demonstrated that the Kd-restricted
influenza nucleoprotein epitope, amino acids 147–155,
cannot be processed and presented when appended by two
COOH-terminal residues, threonine and glycine, due to
the unavailability of appropriate proteolytic activity (21).
Presentation of the epitope can take place when the fragment is coexpressed with the dipeptidyl carboxypeptidase
angiotensin converting enzyme (ACE; references 26 and
27). As rescue is intracellular and TAP-dependent, and this
enzyme is active only in the exocytic compartment, and ACEmediated processing of the 11-mer is a reflection of TAPmediated transport within intact target cells (see Fig. 1 for a
schematic of this process). We have used this system to examine class I–restricted presentation of an array of substrates
that differ significantly in their in vitro transport capabilities.
Materials and Methods
Cell Lines. The L-Kd (L929 transfected with the Kd gene) cell
line was maintained in DMEM, 5% FCS. RMA and RMA-S
cells were maintained in RPMI, 5% FCS.
Peptides and Antibodies. Peptides were acquired from Research
Genetics (Huntsville, AL) and either were obtained at .90% purity or were purified by reverse-phase HPLC. Purified anti-CD8
b subunit antibody 2.43 was provided by Dr. Y. Sykulev (Jefferson Medical College).
PCR-based Mutagenesis and Vaccinia Virus Generation. Minigenes
and minigene-encoding vaccinia (vac) recombinants were generated
as previously described (21) with the following modification: minigenes were made by PCR of the NP/R2 gene. The synthetic oligonucleotide primers used contained a SalI site in the upstream primer
and a NotI site in the downstream primer to enable directional ligation. The downstream primer contained random bases at the
triplet encoding the residue at the “X” position. All minigenes
were preceded by Kozak’s consensus sequence and an initiating
methionine and followed by two stop codons to ensure efficient
and accurate translation (28). After ligation into a modified
pSC11 plasmid, DNA was isolated from random colonies and sequenced to determine the identity of the randomly mutated residue. ACE vac has been previously described (27). Cytosolic ACE
was generated by PCR of the ACE gene. The synthetic oligonucleotide primers used contained a NotI site in the upstream
primer and XhoI in the downstream primer to anneal to a unique
XhoI site within ACE. The upstream primer annealed to the portion of ACE directly after the leader sequence. The PCR product
was cloned into NotI-XhoI cut pBS-KS1-ACE and then shuttled
into the modified pSC11 for recombination into vac. Radioim-
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munoprecipitation of cytosolic ACE vac-infected cells yielded
two rapidly degraded anti-ACE–specific bands as previously observed (27). Generation of the pSC11 plasmid containing the
original thermostable duplex barrier (HP20) construct has been
previously described (29) and contained a KpnI site at the top of
the hairpin loop structure. To generate constructs with two
(HP18), four (HP16), or six (HP14) mismatched bps, synthetic
oligonucleotide pairs encoding the desired changes and designed
to ablate the KpnI site after successful ligation were inserted into
KpnI-SalI cut vector. SalI/NotI-ended 147–155TX (TX) constructs were ligated into these vectors and the resulting plasmids
were used to generate vac recombinants.
Target Cell Sensitization by Vaccinia Virus Infection. L-Kd cells (L929
cells stably expressing the class I Kd molecule at the cell surface)
were trypsinized, washed once with balanced salt solution with
0.1% BSA (BSS/BSA), placed at 2 3 107 cells/ml in BSS/BSA,
and infected for 1 h with 5 PFU/cell vac. Cells were then diluted
with Iscove’s medium and infection proceeded for an additional 3 h.
CTL Assays. CTL assays were performed as described elsewhere (21). Infected cells were pelleted, suspended at 4 3 107
cells/ml in Iscove’s medium with 100 mCi 51Cr, and incubated
for 1 h at 378C. Cells were then washed three times with PBS,
suspended in medium, and combined with NP-specific CTLs.
Targets and CTLs were coincubated for 4 h at 378C, then supernatants were collected and counted. For assays using the partially
blocking anti-CD8 antibodies, CTLs, used at a constant effector/
target ratio of 10:1, were coincubated with the antibody dilutions
for 30 min before addition of the chromium-labeled target cells.
Generation of CTL. CTL populations were generated as previously described (21). BALB/c mice (H-2d haplotype) were injected intraperitoneally with 107 PFU of vac recombinants expressing NPM147–155. After at least 2 wk, splenocytes were
harvested. One-third of total spleen cells was infected with PR8,
washed, and then mixed with the remaining cells in Iscove’s medium. Cultures were harvested after 6 or 7 d and used in CTL assays.
Streptolysin O Peptide Transport Assay. In vitro assay of TAPmediated peptide transport was performed as previously described
(17). RMA cells (3 3 106/sample) were permeabilized with
streptolysin O (2 U/ml; Murex Diagnostics, Norcross, GA) and
incubated for 15 min at 378C with z100 ng radioiodinated reporter peptide (amino acid sequence TVNKTERAY, described
in reference 17, iodinated by the Enzymobead method, Bio-Rad,
Hercules, CA, to a specific activity of z20 mCi/mg), 10 ml 100
mM ATP, and indicated dilutions of competitor peptides. Glycosylated reporter peptide (indicating transport to the exocytic
compartment) was recovered using Con A Sepharose (Pharmacia,
Biotech AB, Uppsala, Sweden) and quantitated on a gamma
counter. The peptides were tested without the initiating methionine due to the predicted action of methionyl aminopeptidase
on the endogenously expressed substrates. Reporter peptide
transport in TAP-minus RMA-S cells was always assessed as a
negative control and typically yielded counts ,2% of those seen
with RMA 1 reporter peptide alone. Samples were done singly
except for RMA cells with no competitor, which was done in
duplicate. The experiment was repeated four times, and each
time yielded similar results.
Measurement of the Kinetics of ACE-mediated Substrate Modification. 10 ng of synthetic peptide was coincubated with ACE
(0.001 U; Sigma Chemical Co., St. Louis, MO) in Hepes-buffered saline, pH 7.3, in a 20-ml reaction. At the indicated time
points, samples were frozen on ethanol/dry ice, and then dried
and analyzed by reverse-phase HPLC. Reactions were monitored
by the disappearance of a peak corresponding to starting substrate.
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Substrate concentrations at the various time points were calculated based on the peak area of 10 nM of starting substrate. Initially both reactions resulted in the appearance, at comparable kinetics, of a species which coeluted with synthetic 147–155. This
species was eventually also destroyed by ACE.
Radioimmunoprecipitation. 106 L-Kd were infected for 1 h with
10 PFU/cell of the indicated vacs in BSS/BSA, followed by the
addition of 1 ml of methionine-free DME containing 70 mCi
[35S]methionine (Amersham Corp., Arlington Heights, IL). Infection proceeded for an additional 5 h and then cells were lysed
in 140 mM NaCl, 10 mM Tris, pH 7.4, 0.5% NP-40, and 2 mM
PMSF. Nuclei were removed at high speed centrifugation, lysates
were precleared with protein A–Sepharose beads overnight, and
were then incubated for 90 min with protein A–Sepharose beads
coupled with the NP-specific antibodies HB65 and H19-S24
(provided by Dr. W. Gerhard, Wistar Institute, Philadelphia, PA).
Washed pellets were boiled in reducing SDS-PAGE sample
buffer, then 10-fold dilutions were made of the supernatant from
the wild-type NP sample for comparison to undiluted supernatants from the HP vacs. Samples were analyzed on an SDS-PAGE
10% gel. Relative band intensities were determined by scanning
the gel with a Personal Densitometer SI (Molecular Dynamics,
Sunnyvale, CA) using a Windows workstation.

Results
ACE-mediated Rescue of a Panel of 11-mer Fragments. A panel
of vacs was generated containing an array of TX minigenes
in which the residue at the COOH-terminal position was
randomly changed. Eight constructs were made, with substitutions representing each of the amino acid types and,
more importantly, representing examples of COOH-terminal residues previously shown to have either a positive or
negative influence on transport (15, 17). All of the constructs studied contain an initiating methionine that is predicted to be removed by methionyl aminopeptidase (30),
and which has therefore been eliminated from the nomenclature.
None of these constructs was presented in the absence of
ACE, reiterating severe limitations on available mono- or
dipeptidyl carboxypeptidase activity suggested by the TG
block of presentation (Fig. 2). When coexpressed with
ACE, every TX vac sensitized target cells for lysis by
NP-specific CTLs. One trivial explanation for this phenomenon is that the COOH-terminal (X) residue may be
cleaved in the cytosol, followed by transport and unconventional ACE-mediated removal of the remaining threonine. To address this possibility, we generated and tested a
vac recombinant that expressed 147–155T (with no X residue). This construct failed to sensitize target cells for NPspecific lysis above background levels, and its presentation
could not be rescued by ACE. Also shown in this figure, a
form of ACE intentionally delivered to the cytosol failed to
process TG and all other TX constructs tested. Taken with
the previous finding that cytosolically delivered ACE is
rapidly degraded and all detectable intracellular wild-type
ACE activity segregates with the glycosylated form of the
enzyme (27), this result indicates that the effects seen in our
system are not due to anomalous expression of small
amounts of ACE within the cytosol, and is consistent with

Figure 2. A panel of 147–155TX minigene-expressing vac recombinants containing random amino acid replacements at the COOH-terminal X position are all transported, processed by ACE, and presented by intact target cells. L-Kd cells were infected for 4 h with 5 PFU of the
indicated vac with 5 PFU of control virus (open bars), or with 5 PFU ACE
vac (solid bars), or cytosolically delivered ACE vac (hatched bars). 51Cr-labeled
target cells were then assessed for recognition by NP147–155-specific CTL
at an effector/target ratio of 50:1. Control virus in these experiments was
NP296–498 vac.

a strict requirement for transport to the exocytic compartment. Thus, each member of the panel is transported sufficiently well within an intact cell to stimulate recognition
and lysis by class I–restricted CTLs in an optimized chromium release assay.
In Vitro Transport of TX Mutant Constructs. Because each
construct sensitized target cells for recognition by CTLs,
we considered the possibility that these substrates do not
differ in their transport capabilities despite the predicted influence of the COOH-terminal replacements (15, 17).
Synthetic versions of selected constructs predicted to be either transport-permissive (147–155TL, –TM) or -nonpermissive (147–155TP, –TE, –TG) were tested for their ability to inhibit TAP-dependent transport of the radiolabeled
reporter peptide, TVNKTERAY (17), in streptolysin O–permeabilized RMA cells (Fig. 3). TL and TM were both welltransported, with IC50 values of z10 mM. TP was transported
at a rate at least a log below that of the well-transported substrates, with inhibition of reporter peptide transport occurring only at substrate concentrations well above those normally tested in this type of assay. Unexpectedly, we frequently
observed an enhancement rather than inhibition of reporter
peptide transport in the presence of both TE and TG. We
are presently investigating this intriguing phenomenon, but
based on this data can only state that neither of these substrates appears to be transported under the conditions of
this assay. This property was also exhibited by the unappended minimal epitope, generally in agreement with a
previously reported IC50 value of .50 mM (14). Therefore,
this panel of substrates exhibits a wide range of in vitro transport capabilities. Note that, although rules regarding the
influence of COOH-terminal residues on transport have
been established on a limited range of test peptides, predictions of transport capability based on these rules were completely borne out.
Purified ACE-mediated Modification of the Synthetic Form of
Each TX Construct. It was necessary to ensure that differences in ACE-mediated substrate modification would not
confound our analysis, perhaps masking true transport dif1658

Figure 3. In vitro transport of synthetic versions of the 147-155TX
constructs. RMA cells were permeabilized with streptolysin O (2 U/ml)
and incubated with radioiodinated reporter peptide (amino acid sequence
TVNKTERAY) plus the indicated dilutions of test peptides. Reporter
peptide transport in TAP-minus RMA-S cells was always assessed as a
negative control and typically yielded counts ,2% of those seen with
RMA 1 reporter peptide alone. Samples were done singly except for
RMA cells with no competitor, done in duplicate. The experiment was
repeated four times, all yielding similar results.

ferences. Purified ACE was incubated with a starting concentration of 10 nM of synthetic peptide. The reaction was
stopped at various time points and the reaction products
were analyzed by reverse-phase HPLC. The kinetics of
ACE-mediated peptide modification were determined by
following the rate of disappearance of the peak representing
starting substrate (Fig. 4). Of the substrates tested, only
ACE-mediated presentation of TE differed significantly from
the other substrates, being modified more slowly. Therefore, this construct was excluded from further analysis. Consistent with this, note that this construct exhibited slightly
but repeatably lower levels of presentation under standard
assay conditions (Fig. 2).
Comparison of Presentation Efficiencies under Suboptimal Conditions. It has been demonstrated that, under the conditions
of vaccinia-driven antigen expression and the time course
of the typical chromium release assays, it can be difficult to
resolve significant differences in presentation efficiencies (9,
31). For example, if only 15 MHC–peptide complexes are
required on the cell surface to stimulate optimal levels of T
cell lysis, then any processing events that yield more than
this relatively small number will stimulate similar lysis levels. To ensure the finest resolution, the assay must be performed under conditions that are suboptimal for T cell recognition. This may be accomplished by limiting the number
of MHC–peptide complexes that reach the cell surface
through the addition of the fungal metabolite brefeldin A
(32–34), by limiting T cell receptor–ligand interaction
through the use of partially blocking anti–T cell receptor or
anti-CD8 antibodies, or by limiting the amount of starting
substrate through genetic manipulations of the test constructs.
Partial T Cell Receptor Blocking with Anti-CD8 Antibodies. When we examined presentation of the epitope from
the various TX contexts following the addition of brefeldin
A at numerous time points after infection, we failed to distinguish presentation differences between them (data not
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Figure 4. Kinetics of purified ACE modification of synthetic substrates.
10 ng synthetic peptide was coincubated with ACE (0.001 U) for the indicated times. Samples were then subjected to reverse-phase HPLC. Reaction rates were monitored by the disappearance of the peak corresponding to starting substrate.

shown). However, the two other approaches described
above yielded more discriminating results. First, we examined ACE-mediated presentation of the constructs in the
presence of increasing doses of purified 2.43, a monoclonal
antibody directed to the b subunit of CD8. Although the
results were somewhat variable between experiments, this
antibody will completely block CTL recognition at doses
of 5–10 mg/ml. As shown in Fig. 5, susceptibility to the
blocking antibodies across the panel of constructs precisely
mirrored the in vitro transport capability of the peptides.
Presentation of TG, which exhibited no detectable transport in streptolysin O–permeabilized cells, was severely inhibited at 1 mg/ml of the antibody. This concentration had
a lesser, but still significant, blocking effect on TP presentation, a poorly transported substrate. The very well transported substrates, TL and TM, showed only slightly suboptimal presentation levels under this condition. This pattern
of differential susceptibility was maintained at decreasing
antibody doses. Even at a concentration of 0.1 mg/ml, perhaps one-tenth the concentration of antibody required to
block optimally expressed peptide complexes, the poorly
transported TG suboptimally sensitized target cells for lysis.
Therefore, under conditions of limited T cell stimulation,
biochemically established rules of transport capability also
appear to apply within the intact cell.
Limiting Starting Levels of Antigen Expression. It is possible that levels of antigen expression resulting from in vitro
vac infection of target cells are higher than those that occur
in many physiological situations. This is particularly a concern with minigene products (31). We therefore wished to
assess presentation when starting substrate expression was
limited. To do this, we made use of a previously described
thermostable duplex barrier, comprised of a hairpin structure containing 20 paired bases (HP20; reference 29).
When placed between the P7.5 vac promoter and the initi1659
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Figure 5. ACE-rescued presentation under conditions of limited T cell
receptor stimulation. L-Kd cells were coinfected for 4 h with 5 PFU of
the indicated vac alone and 5 PFU ACE vac. 51Cr-labeled target cells
were then assessed for recognition by NP147–155-specific CTLs with or
without the indicated concentrations of anti-CD8 antibody 2.43. CTLs
were used at a constant effector/target ratio of 10:1.

ating methionine of the vac-encoded NP, presentation of
three NP epitopes was significantly reduced (29). We extended this approach to include three additional structures,
denoted HP18, HP16, and HP14, each containing two,
four, or six fewer base pairings than the original structure.
This panel was used to try to ensure that we would achieve
suboptimal conditions for each of the TX constructs tested.
To quantitatively ascertain the effects of these barrier
structures on steady state substrate expression levels, the expression of vac-encoded full-length NP was assessed by NPspecific immunoprecipitation of metabolically labeled vacinfected cells. We found that the most thermostable of
these, HP20, reduced NP expression to undetectable levels
(.100-fold reduction) by this biochemical approach, while
HP18 reduced expression by z100-fold. Interestingly, the
HP16 and HP14 structures showed similar decreases of approximately two- to fivefold (Fig. 6).
The panel of TX constructs was placed behind each of
these structures, recombined into vaccinia, and tested for
ACE-mediated presentation. We failed to see significant
presentation of any of the constructs when placed behind
HP20 and thus concentrated our analysis on the three less
stringent barrier hairpins. As shown in Fig. 7, presentation
efficiencies of the constructs across the range of barriers
were consistent with the biochemical and anti-CD8 analy-

Figure 6. Effect of a panel of thermostable duplex barriers on NP expression. (A) Schematic diagram of the hairpin structures. Arrows indicate
the sites of mismatched bps. (B) L-Kd cells were infected for 1 h with 10
PFU of the indicated vacs, followed by an additional 5 h in the presence
of [35S]methionine. Cells were lysed and protein A–Sepharose–cleared lysates were subjected to immunoprecipitation by NP-specific antibodies.

Figure 7. ACE-mediated rescue under conditions of limited starting
substrate. L-Kd cells were coinfected for 4 h with 5 PFU of the indicated
vacs alone and 5 PFU ACE vac. 51Cr-labeled target cells were then assessed
for recognition by NP147–155-specific CTLs. Shown are two independent
experiments. Effector/target ratios were 30:1 for experiment 1 and 28:1
for experiment 2.

ses. For example, the well-transported constructs, TM and
TL, sensitized targets suboptimally when placed behind
both the HP18 and the HP16 barriers. Both achieved optimal presentation when placed behind HP14, the least thermostable of the hairpin structures. TP, a poorly transported
substrate in vitro, exhibited significantly lower presentation
levels in all of the hairpin contexts. In experiment 2, presentation was still suboptimal in the HP14 context. Presentation of the substrate exhibiting no detectable transport in
vitro, TG, was significantly lower in all contexts; presentation was still significantly suboptimal when placed behind
HP14. In fact, in the experiments shown, even wild-type
TG presentation was somewhat lower than the other constructs, although this was not consistently observed (see Fig. 2).
Discussion
We have used ACE-mediated processing in the exocytic
compartment, followed by recognition of the processed
peptide by CTLs, as a way of gauging TAP function within
intact cells. Several endogenously expressed substrates differing only at the COOH-terminal residues were generated
and their presentation efficiencies were compared to the
transport capabilities of synthetic correlates. This approach
allowed comparison of substrates that differed in transport
capability but all contained the same epitope. The analysis
was confined to substrates that could be modified by ACE
with similar kinetics. This eliminated differences in processing, MHC binding, or T cell recognition as confounding factors.
We found that TAP selectivity within the intact cell can
strongly influence T cell responses and that, at least with
regard to the contribution of the COOH-terminal residue,
this selectivity follows previously established rules. However, the in vitro assays do not entirely predict the effects of
transport selectivity. 147-155, TG, and TE (reference 14
and data not shown), despite exhibiting no detectable transport in vitro, can sensitize target cells for CTL lysis. Whether
this is due entirely to the exquisite sensitivity of T cells, or
reflects the presence in the intact cell of factors that enhance
transport efficiency, is not known.
It will be of interest to determine whether established
1660

biochemical results consistently predict effects of TAP
specificity upon T cell responses. Basic and acidic residues
at the COOH terminus, as well as proline and glycine,
studied in this paper, have been shown to have strong negative effects upon transport in vitro (15, 16). However, as
shown in Fig. 4, we were unable to evaluate glutamic acid
due to slower modification of TE by ACE. It may be that
our approach is not feasible for this group of amino acids.
Identity of internal residues and peptide length are also
strong determinants of in vitro transport efficiency. Investigation of the internal residues using the system described
here would likely be challenging. First, changes within the
epitope itself will alter T cell responses, either by modifying
binding to class I or altering contact with T cell receptor,
limiting the number of possible internal changes. Second,
the assay depends upon the absence of antigen processing in
the cytosol and precise processing by a coexpressed protease after transport. With increasing peptide length, these
conditions may be difficult to achieve.
A subtle reduction in the amount of starting substrate, as
small as a twofold reduction in TX minigene expression
levels, allowed for discernment of the effects of TAP selectivity. This is of particular importance given the findings of
Antón et al. (31) that endogenous expression of the NP147–155
minigene results in a 1,000-fold greater number of epitopes
produced than when full-length NP is the starting substrate. This is presumably due to more molecules being
synthesized in a given time frame and to a lack of the requirement for processing in the cytosol. We assume that
expression of the TX minigenes gives rise to roughly the
same peptide numbers as the minigene-encoded minimal
epitope. If this is true, then the least stringent hairpin, HP14,
where expression levels are reduced only 2-fold, may still
give rise to substrate levels z500-fold greater than those
normally seen after cytosolic generation of transportable
peptides from full-length NP. Yet TAP selectivity is clearly
evident in this case, becoming even more so when substrate levels dip to z10-fold more than what would be predicted for full-length NP. This suggests that in the physiologic situation, where antigen is cytosolically processed
before transport, TAP preferences can be a powerful influence on the T cell response. Similarly, by using as little as a
100-fold less anti-CD8 antibody than is required to completely block T cell receptor–ligand interactions, one can
discern differences between well- and poorly transported
substrates. This suggests that TAP selectivity may allow for
qualitatively different responses of low versus high affinity
T cells.
Many investigators have questioned the adaptive value of
limiting the array of epitopes that can access the exocytic
compartment and become available for class I–restricted T
cell recognition. It has been suggested that restrictions imposed by TAP specificity may represent a balance between
the need to generate a variety of epitopes and the necessity
of preventing excessive clonal deletion during the process
of negative selection in the thymus (35). Alternatively, selectivity has been proposed to enhance efficiency of the
processing pathway by minimizing the need to cycle non–
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MHC-binding fragments back into the cytosol for further
destruction (36). To experimentally explore such questions,
it is critical that we employ assay methods that can most

finely discriminate the influences of such processes on T
cell recognition.
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